BFG
CRL icon

Bleakley Financial Group’s Charles River Laboratories CRL Stock Holding History

Bleakley Financial Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-825
Closed -$224K – 1030
2024
Q1 		$224K Buy
+825
New +$197K 0.01% 852
2023
Q3 		– Sell
-1,012
Closed -$213K – 898
2023
Q2 		$213K Sell
1,012
-37
-4% -$7.36K 0.01% 827
2023
Q1 		$212K Sell
1,049
-280
-21% -$63.5K 0.01% 810
2022
Q4 		$290K Buy
+1,329
New +$290K 0.01% 710

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bleakley Financial Group's CRL Position: Q2 2024 in Review

Bleakley Financial Group sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 825 shares — an estimated $224K sold.

Bleakley Financial Group first reported a position in CRL in Q4 2022 and held it in 4 quarters. The position peaked at $290K in Q4 2022. 664 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Bleakley Financial Group reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Bleakley Financial Group sold 825 Charles River Laboratories shares in Q2 2024, an estimated $224K.
  • Bleakley Financial Group first reported a position in Charles River Laboratories in Q4 2022 and held it in 4 quarters.
  • Bleakley Financial Group's Charles River Laboratories position peaked at $290K in Q4 2022.
  • 664 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Bleakley Financial Group's 13F filing for Q2 2024, filed 12 Aug 2024.